Intangible Assets

ARE’s life-science and lab real estate is supported by specialized tenant requirements and long lease structures, which makes location and build-out quality more durable than in generic office peers.

Its portfolio benefits from proximity to major research clusters and university/medical ecosystems, which supports tenant retention versus broader commercial landlords that lack comparable scientific adjacency.

The company’s assets are tied to highly specific use cases, so replacement space is less interchangeable than standard industrial or office properties, though peers such as VTR and DOC can still compete for similar demand pools.

ARE’s tenant relationships are reinforced by mission-critical lab infrastructure, which raises the cost and complexity of relocation relative to conventional REIT peers.

The moat is strong but not dominant because specialized assets can still be replicated over time by well-capitalized competitors in select markets.

Switching Costs

ARE’s tenants face meaningful switching costs because moving lab operations requires reconfiguring equipment, compliance systems, and scientific workflows, which increases retention versus standard office REITs.

Long lease terms and tenant-specific improvements make relocation economically unattractive, which supports pricing power relative to peers with shorter-duration or more commoditized leases.

The company’s facilities often host regulated or highly technical research activity, so downtime risk from moving is higher than in most commercial property categories.

Compared with peers like VTR and DOC, ARE’s tenant base is typically more operationally embedded in the space, which improves renewal probability and reduces churn.

Switching costs are durable but not absolute because large tenants can still consolidate or relocate when economics justify it.

Network Effects

ARE benefits from clustering effects around leading research hubs, where tenant demand is reinforced by proximity to talent, collaborators, and institutions.

A dense tenant ecosystem can improve occupancy and leasing velocity, but this is an indirect local-network benefit rather than a true platform network effect.

The company’s presence in established life-science markets can attract additional tenants to the same submarkets, which is stronger than in fragmented office REITs.

Compared with peers, ARE has a better-developed ecosystem in core innovation corridors, but the effect is still limited by real estate’s inherently local and non-scalable nature.

Because tenants do not become more valuable to each other through the ARE platform itself, the network effect is supportive rather than decisive.

Cost Advantage

ARE does not appear to have a structural cost advantage in the classic sense because lab real estate development and operations remain capital intensive and broadly financeable.

Its scale can improve procurement, development execution, and portfolio management versus smaller peers, but those benefits are incremental rather than hard to replicate.

Negative TTM ROIC and ROCE indicate that current capital deployment is not translating into superior economic returns, which weakens evidence of a durable cost edge.

Compared with peers, ARE may achieve better operating leverage in core markets, but that advantage is offset by high asset intensity and cyclical funding conditions.

The company’s cost position is therefore moderate, with scale benefits present but not strong enough to create a lasting margin gap.

Efficient Scale

ARE operates in a specialized niche where high-quality lab space in top clusters is limited, which supports efficient-scale characteristics versus broader REIT peers.

The market is concentrated enough that a few large owners can matter, but not so concentrated that ARE faces monopoly-like protection from competition.

Its portfolio density in key life-science hubs can improve leasing efficiency and tenant service relative to smaller competitors, which supports retention and pricing.

Compared with VTR and DOC, ARE is more focused on a narrower asset class, which strengthens local scale advantages in the most attractive submarkets.

Efficient scale is one of ARE’s strongest moat drivers, but it remains short of structural dominance because new supply can still enter when returns justify it.

Overall Score

ARE has a strong but not dominant moat, led by efficient scale, switching costs, and specialized intangible asset characteristics in life-science real estate, while network effects and cost advantage are supportive but less decisive versus peers.